Lupin, a global pharmaceutical company, has announced the launch of Prucalopride tablets in the United States. Prucalopride is a serotonin receptor agonist used to treat chronic idiopathic constipation (CIC) in adults. The medication works by increasing the movement of stool through the intestines, helping to relieve symptoms of constipation such as infrequent bowel movements, hard or lumpy stools, and straining during bowel movements.
The launch of Prucalopride tablets in the U.S. marks a significant milestone for Lupin, as it expands the company’s presence in the gastroenterology market. Lupin’s Prucalopride tablets are available in 1mg and 2mg strengths, and are marketed under the brand name Motofen. The medication is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CIC in adults.
Chronic idiopathic constipation is a common gastrointestinal disorder that affects millions of people in the United States. It is characterized by persistent Difficulty with bowel movements, and can have a significant impact on a person’s quality of life. Prucalopride has been shown to be effective in treating CIC, with clinical trials demonstrating significant improvements in bowel movement frequency and consistency.
The launch of Prucalopride tablets in the U.S. is a significant addition to the treatment options available for CIC patients. Lupin’s Motofen is a convenient and effective treatment option that can help patients manage their symptoms and improve their overall quality of life. The medication is available by prescription only, and patients should consult with their healthcare provider to determine the best course of treatment for their individual needs.
Lupin’s launch of Prucalopride tablets in the U.S. is part of the company’s ongoing commitment to expanding its portfolio of specialty medications. The company has a strong focus on developing and commercializing medications that address significant unmet medical needs, and the launch of Motofen is an important step forward in this effort.